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Abstract 
Objective 
To provide a state of the art review of intranasal antiviral drug delivery and to discuss current 
applications, adverse reactions, and future considerations in the management of coronavirus 
disease 2019 (COVID-19). 
Data Sources 
PubMed, Embase, and Clinicaltrials.gov search engines. 
Review Methods 
A structured search of the current literature was performed of dates up to and including April 
2020. Search terms were queried as related to topics of antiviral agents and intranasal 
applications. A series of video conferences was convened among experts in otolaryngology, 
infectious diseases, public health, pharmacology, and virology to review the literature and 
discuss relevant findings. 
Conclusions 
Intranasal drug delivery for antiviral agents has been studied for many years. Several agents 
have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior 
to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the 
settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases. 
Implications for Practice 
Intranasal drug delivery represents an important area of research for COVID-19 and other viral 
diseases. The consideration of any potential adverse reactions is paramount. 
Keywords 
coronavirus, COVID-19, antiviral agents, nasal, nasopharynx, public health, severe acute 
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The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in the immunologically naïve human population has led to a global pandemic. SARS-
CoV-2 is spread primarily through airborne droplet and contact transmission with 
contaminated fomites. While SARS-CoV-2 particles may persist on surfaces for several 
days, as enveloped viruses, they are sensitive to desiccation and mild detergent 
disinfection.1 Small population studies indicate that between 6% and 88% of SARS-
CoV-2 infections do not result in overt disease.2-4 The impact of asymptomatic or 
subclinical individuals to public health is clear, with up to 44% of infected individuals 
having contracted the virus from asymptomatic persons.5 Individuals who display clinical 
symptoms of SARS-CoV-2 infection, or coronavirus disease 2019 (COVID-19), exhibit a 
range of symptom severity, with high case fatality rates in the elderly, 
immunocompromised patients, and those with comorbid diabetes and cardiac, 
pulmonary, and immunocompromised conditions.6 
The nasal cavity and nasopharynx contain some of the highest viral loads in the body, 
and viral loads are similar in symptomatic and asymptomatic individuals. Accordingly, 
these “silent spreaders” may unknowingly contribute to the exponential growth of 
disease, as nasal secretions contain spreadable virus, and contagiousness appears to 
be highest before or shortly after symptom onset. 
Current strategies to mitigate the pandemic have focused on public health initiatives, 
such as social distancing, community hygiene awareness, testing and tracing, and 
travel restrictions. Intranasal delivery of antiviral drugs or agents may provide an 
additional option for preventing disease transmission, treating the nasal disease, and 
providing perioperative antisepsis. This article summarizes our findings for the potential 
role of studying topical intranasal delivery of drugs and agents known to have antiviral 
properties in SARS-CoV-2. 
Methods 
A search of PubMed, Embase, and Clinicaltrials.gov was conducted to identify relevant 
peer-reviewed English articles related to intranasal application of drugs and agents with 
antiviral properties. A multidisciplinary team of specialists in the areas of otolaryngology, 
infectious diseases, public health, pharmacy, and virology was assembled to review and 
summarize the literature. A series of video conferences was held to interpret the 
findings and discuss potential applications of intranasal application of antiviral agents in 
the setting of the COVID-19 pandemic. The panel discussed several topics relevant for 
consideration in intranasal antiviral drug therapy (Figure 1). Agents were assessed for 
evidence of antiviral activity, in SARS-CoV-2 and other viruses, and for efficacy or 
potential feasibility in human intranasal use. Potential intranasal adverse reactions were 
evaluated—specifically, mucosal or skin irritation, smell and taste disturbance, 
headaches, allergic reactions, nasal bleeding, fungal infection or colonization, and 
rhinosinusitis. Additional items of discussion included adequacy of mechanisms of 
target or viral cell infiltration, routes of delivery, medium suspension, additives to 
enhance mucosal or cellular absorption of the agents, and the reliability of compounding 
these substances. 
Discussion 
Viral Structure and Mechanism 
Coronaviruses, such as SARS-CoV-2, are enveloped positive-sense RNA viruses with a 
genome length of approximately 30,000 nucleotides encoding 16 nonstructural proteins 
and at least 4 main structural proteins, although the absolute number varies among the 
members of Coronavirinae (Figure 2).7 Architecturally, coronavirus particles are 
spherical with an average diameter of 125 nm, from which the projection of the spike 
glycoproteins create a crown-like appearance responsible for the name of the genus. In 
addition to the spike glycoproteins, coronavirus particles consist of the E and M integral 
membrane proteins, a host-derived lipid envelope, and the helical viral nucleocapsid 
consisting of the N protein and the viral genomic RNA. 
As summarized in Figure 3, the coronavirus cellular viral life cycle begins with the 
attachment of the viral particle to the host cell via the viral spike glycoprotein.8 The 
cellular receptor involved in viral entry varies among the members of Coronavirinae; 
however, the SARS-CoV-2 virus, in addition to the original SARS virus (SARS-CoV-1) 
and the endemic human coronavirus HCoV-NL63, utilizes the human angiotensin-
converting enzyme 2 protein as its primary receptor.9 The entry of the virus into the host 
cytoplasm requires a series of 2 proteolytic cleavage events of the spike glycoprotein to 
reveal the fusion peptide, which mediates the fusion of the viral and cellular lipid 
bilayers. The delivery of the viral RNA into the cytoplasm results in the expression of the 
viral replicase complex, which consists of 16 nonstructural proteins encoded by the 
genomic RNA. Within the viral replication compartment, viral RNA synthesis produces a 
nested set of mRNA transcripts produced via a complex discontinuous RNA synthesis 
mechanism, which produces complementary negative-sense RNA templates. The 
nested mRNAs produce the remainder of the viral structural proteins, and progeny viral 
genomes are produced by way of continuous viral RNA synthesis. The formation of new 
viral nucleocapsids occurs in the cytoplasm of the infected cells, and mature viral 
particles are budded into the ERGIC (endoplasmic reticulum–Golgi intermediate 
complex) via an interaction between the ERGIC membrane–associated M protein and 
the N protein of the nucleocapsid. The mature viral particles are trafficked to the cell 
membrane in smooth-walled vesicles and released to the extracellular space. 
To date, 7 coronaviruses capable of infecting humans have been identified and account 
for 5% to 10% of acute respiratory infections. Most endemic coronaviruses cause self-
limiting upper respiratory infections; however, SARS-CoV, SARS-CoV-2, and Middle 
Eastern respiratory syndrome coronavirus (MERS-CoV) have notably high mortality 
rates.7 Transmission of SARS-CoV-2 appears to occur primarily through respiratory 
droplets,6 with secondary surface contact transmission and aerosol transmission 
possible. The incubation time is typically 3 to 7 days, with up to 2 weeks between time 
of infection and symptoms. This long asymptomatic phase is thought to contribute to the 
large basic reproduction number (R0) of 2.5 to 3.10 Viral shedding has been detected in 
multiple anatomic sites, including the nasal cavities, nasopharynx, sputum, oropharynx, 
bronchial fluid, and stool.11 However, the nasopharynx had a much higher detection rate 
than the oropharynx.12 
Agents With Antiviral Capability 
While no drug has been developed to specifically treat the SARS-CoV-2 virus, a few 
agents have been found to inactivate SARS-CoV-2 on surfaces, including ultraviolet 
(UV) radiation, heat, ether, ethanol, and isopropanol.6 Other agents have been studied 
with other viruses. Table 1 shows a summary of the antiviral agents discussed. 
The World Health Organization (WHO) guidelines on hand hygiene in health care 
contain 2 alcohol-based formulations: ethanol and isopropanol.13 These compounds are 
fast acting, inexpensive, and broad spectrum, previously showing the ability to inactivate 
SARS-CoV14 and MERS-CoV.15 WHO recommends the use of at least 60% ethanol or 
70% isopropanol in hand sanitizer formulations.16 However, there is evidence that both 
alcohols inactivate the SARS-CoV-2 down to a concentration of 30%.17 
Intranasal application of alcohol formulations was studied in a placebo-controlled 
randomized controlled trial (RCT) of 387 health care workers.18 Health care workers 
colonized with nasal Staphylococcus aureus were swabbed intranasally 3 times a day 
with 70% ethanol combined with natural oil emollients and the preservative 
benzalkonium chloride or placebo. Antiseptic use reduced S aureus colony-forming 
units by a median of 99% (P < .001) as compared with placebo. The participants 
reported no adverse effects during the study. 
Povidone-Iodine 
Povidone-iodine (PI) has rapid bactericidal and virucidal activity, including against 
SARS-CoV and MERS-CoV.19 It is widely available in the clinical settings and has been 
utilized as a skin disinfectant as well as an oral wash or gargle rinse. 3M developed and 
evaluated an intranasal formulation application (PI solution, 5% wt/wt [0.5% available 
iodine]; United States Pharmacopeia) to the anterior nares. A blinded expert grader’s 
assessment of the level of intranasal skin erythema and edema in 30 patients 
demonstrated no significant irritation by the Draize scale. Formulations of 5% to 10% PI 
have been evaluated intranasally with regard to potential side effects, and results have 
shown no gross injury, though ciliotoxicity has been demonstrated in vitro at these 
concentrations.20 An RCT of nasal application of 10% PI, 5% PI, or placebo 
preoperatively for arthroscopic surgery for methicillin-resistant S aureus prophylaxis 
found equal rates of nasal irritation.21 An in vitro study of free iodine of PI showed an 
association between free iodine concentration and virucidal efficacy.22 However, a study 
of 5% and 10% PI applied to ciliated human respiratory epithelial cells showed 
ciliotoxicity.23 Lower-concentration formulations (0.5% PI [Nasodine]) applied in vitro to 
air-liquid interface cultures of primary human nasal epithelial cells were found to lack 
cytotoxicity or ciliotoxic effect.24 Calls for the consideration of PI application intranasally 
or orally has been advocated as a preventative for patients and health care workers 
involved in head and neck oncologic care who are at risk of COVID-19 
exposure.25,26 Aspiration pneumonitis has been reported following surgery using oral PI 
as well as staining of the teeth and tongue.27 A search of Clinicaltrials.gov revealed that 
a few study groups initiated protocols to evaluate intranasal or intraoral formulations of 
PI for SARS-CoV-2.28-31 
Carrageenan 
Carrageenan is a polysaccharide extracted from red seaweed that is widely used as a 
thickening agent for food. In vitro and animal studies demonstrate that carrageenan 
shows antiviral properties to human rhinovirus and influenza A and prevents viral 
attachment to host cells without systemic absorption or nasal mucosal penetration. Four 
placebo-controlled RCTs evaluated iota-carrageenan nasal spray in the treatment of 
respiratory viral infections (including rhinovirus, enteroviruses, and influenza) with 
variable reduction in symptoms and viral loads versus placebo saline 
spray.32,33 Formulations of nasal sprays containing carrageenan are available over the 
counter, but the Food and Drug Administration (FDA) currently has approved this agent 
only as a food additive permitted for human consumption. 
Acid-Buffered Saline 
Acidic pH is frequently used for virus inactivation. Acidic solutions are commonly used in 
the pharmaceutical industry to inactivate viruses in the isolation of viral proteins and for 
cleaning and prevention of infection.34,35 Acid-buffered saline has been investigated as a 
topical therapy for various upper respiratory viruses, showing inactivation of influenza A, 
decreased symptoms and viral shedding of influenza A, reduced viral shedding of 
human rhinovirus with the use of solutions and nasal gels, and reduced symptom 
severity and duration of illness in the common cold.34,36 Unfortunately, SARS-CoV-2 has 
been shown to be highly stable in a range of pH environments, limiting the viability of 
acidic therapies as options against this virus.1 
Hypertonic Saline 
Hypertonic saline may reduce symptoms of various upper respiratory viruses as well as 
potentially decrease viral shedding and promote inactivation.37,38 Ramalingam et al 
demonstrated via in vitro studies that increasing the availability of NaCl may facilitate 
the innate immune response in nonmyeloid cells via an increase in intracellular 
hypochlorous acid levels.38 In an RCT of hypertonic saline irrigation and gargling for the 
common cold, Ramalingam et al found that the use of hypertonic saline reduced 
symptom severity, length of illness, intrahousehold transmission, and viral 
shedding.37 Meta-analyses have shown good tolerability with some reports of nasal 
irritation, headache, and epistaxis.39 
Hydrogen Peroxide 
Hydrogen peroxide (H2O2) has long been known to cause viral inactivation, and 
H2O2 0.5% efficiently deactivates SARS-CoV-2 on surfaces.40,41 While H2O2 is 
commonly used for surface, surgical, and oral disinfection,40 there are currently no 
human clinical trials demonstrating the safety or efficacy of intranasal application of 
H2O2. 
Probiotics 
The use of ingested oral probiotics has been evaluated in the current COVID-19 
pandemic, but the evidence of its use is from small case series and correspondences, 
and experts concluded that even if oral probiotics were useful, they were unlikely to 
have a direct effect on the severe acute respiratory syndrome that most patients with 
COVID-19 present.42 However, there is evidence that the nasal and gastrointestinal 
microbiomes are important factors in the innate immune system and particularly in the 
defense against respiratory viral pathogens. Nasal microbiota clusters were found 
associated with host inflammatory response, viral load, and symptom severity in 
rhinovirus.43 The Corynebacterium-rich cluster of patients had overall reduced 
symptoms during rhinovirus infection despite the addition of oral probiotics not 
significantly changing the host microbiome (nasal and 
gastrointestinal). Corynebacterium was also found to be protective against respiratory 
syncytial virus infection in an in vivo mouse model.44 Also, in a mouse model, Zelaya et 
al found that Lactobacillus introduced nasally helped prevent influenza pulmonary 
damage and inflammation.45 While the effects of orally administered probiotics on a 
variety of viruses has been studied, we found no studies directly investigating the 
introduction of intranasal probiotics for the treatment of human upper respiratory virus 
infections. Further studies on nasal and oral administration of probiotics are warranted 
for COVID-19 and other upper respiratory viral infections. 
Surfactants/Shampoo 
Surfactants and, in particular, baby shampoo have been studied most extensively in 
chronic rhinosinusitis. Most studies have evaluated potential bactericidal and antibiofilm 
effects.46 We found no studies that evaluated surfactant application to the nasal cavity 
and its ability to prevent or diminish viral infection. However, intrinsic pulmonary 
surfactant has been found to be an important part of our innate immune system, and its 
use was recently shown to help prevent several respiratory viruses, such as H1N1 and 
influenza.47-49 The pulmonary surfactant phospholipids are thought to prevent viral 
infections by inhibiting viral binding to epithelial cells. The use of surfactants to achieve 
the same results in the upper aerodigestive tract is intriguing but has not been studied. 
One proposed trial aims to investigate the effect of saline irrigations and baby 
shampoo/saline irrigations on patients with COVID-19.50 Most surfactants have been 
reported to have good tolerability, but it is worthy to note that surfactant additive in nasal 
saline rinses has been associated with nasal congestion and temporary smell loss in 
healthy volunteers.51 
UV Radiation 
Based on the physiologic effects, UV radiation can be divided as follows: UV-C (100-
280 nm), UV-B (280-320 nm), and UV-A (320-400 nm). The majority of evidence of the 
biological effect of UV light has come from the field of dermatology, where various forms 
of phototherapy have been applied for decades.52 
Intranasal phototherapy has been explored for the treatment of other rhinologic 
conditions, primarily based on its immunomodulating effect on inflammatory processes. 
Two RCTs demonstrated that combined low-dose UV-B, low-dose UV-A, and visible 
light are effective in reducing symptom scores of moderate to severe ragweed-induced 
allergic rhinitis uncontrolled by antiallergic drugs.53,54 However, a similar treatment 
protocol does not appear to have efficacy for treatment effective for chronic 
rhinosinusitis.55 
The carcinogenic risk of rhinophototherapy on the nasal mucosa appears to be limited 
at the exposure levels used in the studies cited. Nasal epithelial cells are capable of 
repairing UV-induced DNA damage in patients with allergic rhinitis who are receiving 
intranasal phototherapy.56 Significant DNA damage was observed immediately after 
completion of 2 weeks’ treatment, which was reduced at the 10-day assessment but 
equivalent to the control group at 2-month follow-up. Parallel experiments demonstrated 
similar repair kinetics in human skin in vitro and animal models.57 Animal studies with 
UV-A and UV-B irradiation demonstrate no histopathologic changes58 and no induction 
of apoptosis at lower doses.59 Other animal studies have shown similar reduction in 
histopathologic changes with phototherapy as compared with nasal corticosteroid 
treatment without increasing apoptosis of mucosal cells.60 
UV-C is strongly absorbed by the nucleic acids of microorganisms and therefore is the 
most lethal range of wavelengths for them. UV-C sterilization has been proposed as an 
effective method for simultaneous disinfection of the water source and saline irrigation 
bottle61 and has been used in combination to reduce titers of SARS-CoV-2 to 
nondetectable levels in human blood transfusion products.62 
Multiple clinical studies dating back to the 1940s63 demonstrated that UV exposure of 
the wound during surgery resulted in markedly decreased surgical site infection rates. 
However, conventional UV-C light sources, typically emitting at 254 nm, are a human 
health hazard, causing skin cancer and cataracts.64,65 In contrast, far-UV-C light in the 
range of 207 to 222 nm has the same bactericidal potential of 254-nm light but without 
the damaging effects to mammalian cells and tissues. Due to its short range in 
biological materials, far-UV-C light does not penetrate the outer layer of the skin or the 
outer surface of the eyes but can efficiently inactivate the nucleic acids and proliferative 
capacity of surface microbes.66,67 
While intranasal UV-A and UV-B light is safe, phototherapy at this wavelength has 
limited antimicrobial activity. UV-C light is an effective method for sterilization, but the 
intranasal safety profile for UV-C phototherapy has not been studied. 
Oxymetazoline and Xylometazoline 
Oxymetazoline and xylometazoline are commonly used over-the-counter nasal 
decongestants. Adverse effects include local irritation and rhinitis medicamentosa, in 
which overuse causes paradoxical nasal obstruction. Small studies have shown 
transient decreased viral load in rhinovirus via topical oxymetazoline nasal 
spray.68 These agents have not been studied in other viruses or SARS-CoV-2. Given 
that they have been shown to reduce rhinovirus viral load, caution may be advisable 
with their use prior to nasal swab viral testing. 
Interferon 
Interferons are complex cytokines intricately involved in innate cellular immunity and are 
named for their ability to interfere with viral replication. Interferons increase expression 
of major histocompatibility complex (MHC) molecules. Increased MHC I expression 
upregulates viral presentation to cytotoxic T cells. Stimulation of MHC II expression 
potentiates helper T-cell response and subsequent release of cytokines that increase 
activity of other immune cells.69 
Viral cellular invasion activated type 1 interferons, which secrete fibroblasts and 
monocytes with interferon-specific receptors. Subsequently, this activates the classical 
JAK-STAT signaling pathway (Janus kinase–signal transducer and activator of 
transcription). The downstream result is an expression of proteins that inhibit viral 
replication.69 The role of interferon in SARS-CoV-2 is intriguing but duplicitous. The 
SARS-CoV-2 virus enters the cell following binding of a spike protein domain with the 
ACE2 receptor, which is upregulated by interferons and has been suggested to help 
lung cells tolerate damage. However, in the case of SARS-CoV-2, the upregulation of 
ACE2 may actually exacerbate the disease. It is unclear if SARS-CoV-2 is utilizing the 
important role of interferon in our innate clinical immunity or if the beneficial effects of 
interferon outweigh the increased cellular entry that it allows.70 
Interferons have been investigated for use against SARS-CoV. An in vitro study of cell 
lines from patients infected with SARS-CoV showed that interferon alpha, beta, and 
gamma all inhibited SARS-CoV replication; however, interferon beta was 5 to 10 times 
more effective and showed prophylactic protection as well as antiviral potential after 
infection.71 Others suggest that type 3 interferons—specifically, interferon lambda—
could be a better therapeutic option in respiratory infections. Sun et al showed that 
interferon lambda was superior to type 1 interferons due to their specificity in the 
respiratory tract, thereby decreasing systemic side effects—specifically, an 
inflammatory response that is sometimes characterized by type 1 interferons.72 
Aerosolized interferon treatment has been shown to be effective in viral-mediated 
respiratory disease. Type 1 interferons have been shown to induce undesirable 
systemic side effects, such as fatigue, headache, pyrexia, myalgia, rigors, and 
psychiatric symptoms. However, topical formulations of recombinant human interferon 
alpha-2b have been shown to have no significant systemic side effects.73 This 
formulation was used as a topical nasal spray in a placebo-controlled trial in children 
with hand-foot-and-mouth disease. The children treated with the topical nasal interferon 
alpha-2b had a shorter duration of fever, fewer oral ulcers, less skin rash, and 
decreased appetite when compared with the placebo group.73 A new formulation of type 
1 interferon—interferon beta-1a—was used in a double-blind, placebo-controlled trial of 
patients with asthma in attempts to decrease viral respiratory infections and, thus, 
asthma exacerbations (NCT 01126177). The proprietary interferon beta-1a formulation 
is the only aqueous preparation and is pH balanced to the respiratory mucosa, making it 
an ideal therapeutic for inhalation. Although this study failed to meet its primary end 
point of better asthma control, it did show good evidence of enhanced innate immunity 
with increased production of antiviral genes in induced sputum.74 
Topical interferon is an intriguing target for SARS-CoV-2 therapy. Preliminary results of 
its use as a prophylactic for health care workers in Hubei, China, show no infections in 
the 2944 health care workers using the medication as a nasal drop.75 While well-
conducted prospective trials are certainly needed in peer-reviewed literature, this 
therapy offers immense promise as a well-tolerated, easy-to-deliver topical prophylactic 
against SARS-CoV-2 infection. 
Enhancing Mucosal Absorption Efficiency 
The advantages in nasal mucosa as a drug delivery medium include increased 
absorption rate, possible increased bioavailability through avoidance of hepatic first-
pass metabolism, and a less acidic pH environment. However, challenges include poor 
retention time on membrane, narrow absorption value, degradation via mucolytic 
enzymes, and continuous mucociliary movement leading to washout.76 
Chitosan 
Chitosan is a cationic polysaccharide widely studied for its mucoadhesive-enhancing 
properties in medication delivery. Chitosan can contain an array of chemically altered 
functional groups to enhance mucoadhesive properties and permeation effects via 
opening of epithelial tight junctions, and several studies have demonstrated superiority 
in chitosan-bound medications as compared with unbound forms. Currently, chitosan 
has FDA-approved uses as a wound-healing agent. However, limited study has been 
conducted on nasal chitosan-based antiviral medications. Given chitosan’s flexibility and 
study as a strong mucoadhesive with generally low toxicity, more research is needed 
into possible nasal chitosan-based antiviral medications.77 
Liposomes 
Lipophilic/liposomal formulations have aided drug delivery across lipid bilayer cell 
membranes. Many FDA-approved medications, such as doxorubicin, amphotericin B, 
and others, have liposomal drug formulations. Several in vitro and in vivo animal studies 
have found liposomal formulations to improve drug bioavailability across the mucosal 
membrane barrier. However, despite the significant quantity of research around 
chitosan and liposomal nasal nanoparticle formulations, there remains no FDA-
approved products of chitosan- and liposomal-based nasal drug delivery systems, and 
further research in humans is needed to support clinical safety and efficacy.78 
Poloxamers 
Poloxamers are a class of hydrogels that are water-soluble and nonionic copolymers 
with amphiphilic and surface-active properties. Increasing temperature of their aqueous 
solutions creates a sol-to-gel transition above a critical gelation temperature. Hydrogels 
are used to facilitate localized sustained release of a drug, thereby lowering drug 
dosage, limiting administration frequency, and avoiding adverse effects. Poloxamers are 
FDA approved as a nontoxic solubilizer, emulsifier, and stabilizer and can be 
administered through oral, parenteral, and topical routes.79 
Route and Medium of Drug Delivery 
Solution Sprays 
Intranasal drug delivery has been used for allergic rhinitis, chronic rhinosinusitis, opioid 
overdose, and topical anesthesia/decongestion for many years and has been widely 
studied in the literature.80 Factors that make this delivery option favorable are the 
relative ease of use in a home environment and good patient tolerance. The risk of 
inducing viral shedding is unknown, as these sprays are aerosolized and could elicit 
sneeze or coughing. Most sprays generate an aerosol that deposits in the anterior nasal 
cavity, with mucociliary clearance carrying medications deeper into the nasal cavity. 
Newer exhalation delivery nasal sprays have been shown to distribute farther within the 
nasal cavity (Figure 4).81 Nasal nebulizers have also been employed in the treatment of 
chronic rhinosinusitis and nasal polyposis; however, distribution of medication is not 
significantly different than that of the exhalation delivery systems and has higher 
associated equipment cost. The mucous layer within the nose renews within 20 minutes 
and is discarded into the nasopharynx; thus, the speed at which the medication 
dissolves within the mucous layer and penetrates mucosa is critical for drug efficacy. 
Computational fluid dynamics could be utilized to determine appropriate particle size, 
spray velocity, and dosing to help guide effective therapies. 
Saline Rinses 
Like solution sprays, intranasal saline rinses are widely available, utilized with and 
without the addition of medications, and generally well tolerated. Further investigation 
on the risk of viral shedding is needed. Advantages suggested over sprays include the 
removal of the mucous barrier with the rinse action to provide maximum interface 
between the drug and the mucosa itself.82 However, formulations of medications must 
be water soluble to administer in this method. 
Gel 
Intranasal nanogels have been utilized for drug delivery in Alzheimer’s disease, 
migraines, depression, and schizophrenia.83 This medium can be utlizied for hydrophilic 
and hydrophobic drugs, distinguishing it from the aforementioned intranasal sprays and 
rinses that typically require a suspension. Additionally, the increased viscosity of the gel 
formulation may increase the residence time of the drug on the nasal mucosa, therefore 
increasing drug absorption through the mucosa.84 Increasing the viscosity may, in turn, 
interfere with normal ciliary beating and cause untoward negative side effects. 
Challenges include maintaining stable formulations with consistent dosing while 
preserving an adequate shelf life and designing an efficient delivery system to 
administer the gel within the nasal cavity. Wang et al85 also proposed a hybrid of 
technologies via an in situ gel-forming system, where a solution instilled intranasally 
undergoes phase transition to a viscoelastic gel. Advantages of this system include 
increased retention in the nasal cavity and increased permeability through the mucous 
membranes. 
Foam/Packing 
Intranasal foam and dissolvable packing have been utilized for many years by 
otolaryngologists for treatment of epistaxis, chronic rhinosinusitis, and postsurgical 
sinus cavities. Applications for drug delivery for psychiatric conditions, such as bipolar 
disorder and schizophrenia, have also been studied. Examples of intranasal foams 
include chitosan, carboxymethylcellulose, hyaluronic acid, and synthetic polyurethane 
foam. Nanoparticles used as reservoirs for hydrophobic drugs can be compounded 
within these foams to provide increased mucoadhesive properties and enhanced 
absorption of medications. This method would likely be more challenging for patients to 
self-administer, as most otolaryngologists employ its use by direct administration by a 
medical professional rather than by patients themselves. Additionally, these foams are 
traditionally applied under at least topical anesthesia and may be less tolerated by 
eliciting more sneezing and irritation than sprays/rinses. 
Dry Powders 
Most intranasal sprays on the market are liquid suspensions; however, recreational 
drugs have been used in powder form for many years. More recently, dry mist nasal 
sprays have been introduced, which dissolves the medication in hydrofluoroalkane 
propellant. Nonaqueous propellants such as propylene glycol, isopropyl alcohol, and 
PEG400 are known to cause local irritation with chronic use; thus, careful attention to 
the choice of propellant and possible adverse reactions must be considered. Other 
challenges for utilization of powders include being able to distribute within the nasal 
cavity, controlling the particle size, protecting the powder’s viability from humidification 
during storage, and maximizing absorption by the mucous membranes.81 
Ointment 
Nasal ointments have been in use for control of folliculitis within the nasal vestibule as 
well as for prevention of epistaxis; however, more recently, interest has increased in 
drug delivery via nasal ointments, such as that for allergic rhinitis.86 Via intranasal 
swabs, these ointments are easily applied by patients to the anterior nasal vestibule, 
with mucociliary clearance carrying medications farther within the nasal cavity. The 
higher-viscosity ointments again result in lower tendency to spread and may increase 
retention time within the nasal cavity. The lipophilic properties of the ointment may also 
enhance absorption by the nasal mucosa. Disadvantages of ointments, specifically 
long-chain mineral hydrocarbons, include risk of paraffin granulomas and case reports 
of lipoid pneumonia from long-term nocturnal intranasal application.86 
Implications for Practice 
Topical intranasal antiviral drug delivery has several potential applications, but further 
studies are necessary. Efficacy in many settings is currently unknown, and 
considerations for any potential adverse effects, including loss of taste and smell, 
epistaxis, and mucosal irritation, are important. For example, while zinc-dependent 
processes have become a target for SARS-CoV-2 therapies due to its modulating effect 
on ACE2,87 a zinc nasal spray was pulled from the market in the past after multiple 
cases of smell loss became public and a case series described zinc-induced anosmia.88 
The panel discussed the following settings in which studies of topical intranasal delivery 
of antiviral medications could be considered (Figure 5): 
 Perioperative prevention for health care workers and patients 
 Prevention of the well person from contracting the virus 
 Prevention of the infected person or presymptomatic carriers from spreading the 
virus 
 Systemic drug delivery 
 Treatment of intranasal viral disease 
 Reduction in progression of viral disease 
Perioperative application as an antiseptic is the most mentioned use of intranasal (as 
well intraoral) antiviral agents. Several articles have described considerations of PI 
usage during oral and head and neck surgery, as well as in-office application for 
prevention of viral spread during minor endoscopic procedures, such as diagnostic 
nasal endoscopy and flexible fiberoptic nasolaryngoscopy.24,25 While clinical settings 
are the ideal initial areas for investigation, studies of community populations could be 
considered for the widespread prevention of spread and as potential therapeutic 
options for nasal symptomatology. 
The nasal cavities and nasopharynx harbor a significant amount of SARS-CoV-2, even 
in asymptomatic or presymptomatic carriers of the virus. Several possible candidates 
exist for intranasal delivery of virucidal drugs and agents; however, clinical efficacy 
would require the agents to have adequate mechanisms of target or viral cellular 
infiltration with routes of delivery and medium suspension to reach the pathologic 
areas. Cellular absorption enhancement agents may also be needed to increase 
effectiveness. As with any therapeutic agent, proper safety profiles for intranasal use 
are important. This article summarizes the current knowledge from the literature 
regarding intranasal drug delivery and its potential applications in combating the SARS-
CoV-2 pandemic and other future viral epidemics. 
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Figure 1. Mind map displaying the ideas and concepts of intranasal drug delivery in the
setting of antiviral disease, including SARS-CoV-2. The central topic has branches
extending radially to connect subtopics. Each subtopic is connected to key concepts.
Figure 2. Structure of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2).
Figure 3. The life cycle of SARS-CoV-2 in host cells. ACE2, angiotensin-converting
enzyme 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment.
Reprinted from Shereen et al (2020).8
Figure 4. Gamma camera image information from the nasal cavity superimposed on the
corresponding sagittal MRI section presenting deposition two minutes after delivery using:
(A) a traditional liquid spray, (B) the breath-powered powder device, and (C) the breath-
powered liquid spray device incorporating the same spray pump. Reprinted from
Djupesland et al (2012).81
Figure 5. Potential applications of intranasal drug delivery.
Table 1. Evidence for Topical Intranasal Antiviral Therapies. 
 
Agents (antiviral mechanism) 
SARS-CoV-2 
   
Other viruses 
  
In vitro activity In vivo activity Clinical efficacy 
 
In vitro activity In vivo activity Clinical efficacy Adverse reactions a Conclusion 
Alcohol and isopropanol (virucidal) 
+ NS NS +, SARS-CoV-1, NS NS +: I; NS: ST, H, A, Alcohol and isopropanol surface preparations have 
   MERS-CoV   B, F, RS rapid virucidal effects on SARS-CoV-2 and other 
       viruses, but they can cause nasal irritation. An 
       intranasal swab application has shown antibacterial 
       properties without nasal irritation. 
Hydrogen peroxide (virucidal) 





H2O2 has long been used as a disinfecting agent and 
has efficacy against SARS-CoV-2 and other viruses 
in vitro. Intranasal safety profile is unknown. 






Carrageenan (prevents viral attachment) 
NS NS + : I  ( 5%), A; 
–: I (S0.5%); NS: 
ST, H, A, B, F, RS 
Anterior nasal formulations are tolerated well. In 
vitro preparations have shown rapid virucidal 
effects to SARS-CoV-2 and other viruses. Human 
adverse effect profile is incomplete. Povidone- 
iodine may have ciliotoxic effects and smell/taste 
loss has not been evaluated. 
 
NS NS NS +, rhinovirus, +, rhinovirus +, rhinovirus NS: ST, H, A, B, F, Carrageenan nasal sprays have shown efficacy in 
   enterovirus,   RS reducing viral loads and symptoms versus placebo 
   influenza    in several randomized controlled trials. No nasal 
       irritation were noted, but other adverse effects 
       were not evaluated. 
Acid-buffered saline (virucidal) 
NS NS NS + +, rhinovirus, 
influenza 
 
Hypertonic saline (promotes innate antiviral immune response) 
 
+, rhinovirus NS: ST, H, A, B, F, 
RS 
 
Acid-buffered saline nasal gels have been used in 
several studies demonstrating ability to reduce 
viral load and symptoms. 




+: I, H, B; NS: ST, 
A, F, RS 
Hypertonic saline irrigation is well tolerated with 
minor discomfort in many other diseases and has 
been shown to reduce symptoms, viral shedding, 
and transmission of the common cold. 
Table 1. (continued) 




Probiotics (may promote innate immunity and antibody production) 






Surfactants/shampoo (prevents viral plasma membrane fusion) 
 
+: I; NS: ST, H, A, 
B, F, RS 
 
Nasal probiotics have been shown to be well 
tolerated in chronic rhinosinusitis but have not 
been studied for antiviral purposes. Oral 
probiotics have shown efficacy in animal and 
human studies with common upper respiratory 
viruses 
 
NS NS NS + +, H1N1, NS +: I, ST; NS: H, A, Surfactant has been shown in vitro and in vivo 
    influenza  B, F, RS; (lungs) to have antiviral properties. Nasal 
       surfactant or shampoo rinses are usually well 
       tolerated but have had reports of nasal irritation 
       and reversible smell loss. Intranasal surfactant 














NS: I, ST, H, A, B, F, 
 
UV-C radiation is virucidal to SARS-CoV-2, but its 
      RS use intranasally and its safety profile have not been 
       studied. Far UV-C light may be less harmful but 
       retain its antimicrobial properties. 
Oxymetazoline and xylometazoline (unknown) 
NS NS NS NS + + +: I; NS: ST, H, A, Small study shows that nasal decongestant may 
     B, F, RS reduce viral shedding temporarily in rhinovirus. 
      Extended use is known to cause mucosal irritation 
      and rebound nasal congestion. 
Interferon (multiple pathways) 
NS + + +, SARS-CoV-1 +, HFMD, 
influenza 
+, HFMD NS: ST, H, A, B, F, 
RS 
Systemic interferon induces multiple side effects, but 
intranasal preparations have been shown to have 
antiviral properties and be well tolerated. Topical 
nasal drops were used as prophylaxis in health 
care workers in Hubei, China, during the beginning 




Abbreviations: +, yes, there is evidence; –, no, there is evidence against statement; HFMD, hand-foot-mouth disease; MERS-CoV, Middle East respiratory syndrome coronavirus; NS, not studied; SARS-CoV, severe 
acute respiratory syndrome coronavirus; UV, ultraviolet. 
aMucosal or skin irritation (I), smell and taste disturbance (ST), headaches (H), allergic reactions (A), nasal bleeding (B), fungal infection or colonization (F), and rhinosinusitis (RS). 
SARS-CoV-2 
   
Other viruses 
 
In vitro activity In vivo activity Clinical efficacy 
 
In vitro activity In vivo activity Clinical efficacy Adverse reactions a Conclusion 
 
